For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 14,547,332 | |||
| General and administrative expenses | 9,722,354 | |||
| Total operating expenses | 24,269,686 | |||
| Loss from operations | -24,269,686 | |||
| Interest income | 313,954 | |||
| Grant income | 361,350 | |||
| Change in fair value of warrant liability | -1,198,210 | |||
| Other income (expense) net | 1,873,514 | |||
| Net loss | -22,396,172 | |||
| Basic EPS | -0.7 | |||
| Diluted EPS | -0.7 | |||
| Basic Average Shares | 32,114,608 | |||
| Diluted Average Shares | 32,114,608 | |||
MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology, Inc. (MAIA)